Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy
Open Access
- 14 August 2013
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 116
Abstract
Background: Diabetes is associated with a high incidence of macrovascular disease (MVD), including peripheral and coronary artery disease. Circulating soluble-Klotho (sKlotho) is produced in the kidney and is a putative anti-aging and vasculoprotective hormone. Reduced Klotho levels may therefore increase cardiovascular risk in diabetes. We investigated if sKlotho levels are decreased in type 2 diabetes and associate with MVD in the absence of diabetic nephropathy, and whether hyperglycemia affects renal Klotho production in vitro and in vivo. Methods: sKlotho levels were determined with ELISA in diabetic and non-diabetic patients with and without MVD, and healthy control subjects. Human renal tubular epithelial cells (TECs) were isolated and exposed to high glucose levels (15 and 30 mM) in vitro and Klotho levels were measured with qPCR and quantitative immunofluorescence. Klotho mRNA expression was quantified in kidneys obtained from long term (3 and 8 months) diabetic Ins2Akita mice and normoglycemic control mice. Results: No significant differences in sKlotho levels were observed between diabetic patients with and without MVD (527 (433–704) pg/mL, n = 35), non-diabetic MVD patients (517 (349–571) pg/mL, n = 27), and healthy control subjects (435 (346–663) pg/mL, n = 15). High glucose (15 and 30 mM) did not alter Klotho expression in TECs. Long-term hyperglycemia in diabetic Ins2Akita mice (characterized by increased HbA1c levels [12.9 ± 0.3% (3 months) and 11.3 ± 2.0% (8 months)], p < 0.05 vs. non-diabetic mice) did not affect renal Klotho mRNA expression. Conclusions: These data indicate that sKlotho levels are not affected in type 2 diabetes patients with and without MVD. Furthermore, hyperglycemia per se does not affect renal Klotho production. As type 2 diabetes does not alter sKlotho levels, sKlotho does not seem to play a major role in the pathogenesis of MVD in type 2 diabetes.Keywords
This publication has 18 references indexed in Scilit:
- Validation of an Immunoassay for Soluble Klotho ProteinAmerican Journal of Clinical Pathology, 2012
- Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretionKidney International, 2012
- Plasma Klotho and Cardiovascular Disease in AdultsJournal of the American Geriatrics Society, 2011
- Role of Klotho in Aging, Phosphate Metabolism, and CKDAmerican Journal of Kidney Diseases, 2011
- Klotho protein diminishes endothelial apoptosis and senescence via a mitogen‐activated kinase pathwayGeriatrics & Gerontology International, 2011
- Klotho Deficiency Causes Vascular Calcification in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Klotho and agingBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Diabetes and AtherosclerosisJAMA, 2002
- Klotho Protein Protects against Endothelial DysfunctionBiochemical and Biophysical Research Communications, 1998
- Mutation of the mouse klotho gene leads to a syndrome resembling ageingNature, 1997